Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
Authors:
Open Access
- 9 April 2020
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 4 (4) , 283-290
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Mutation status of RAD51C,PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutationsCancer Science, 2017
- Endometrial cancerThe Lancet, 2016
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- Molecular targets and targeted therapeutics in endometrial cancerCurrent Opinion in Oncology, 2012
- RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancerCarcinogenesis, 2010
- Activation of BRCA1/BRCA2-Associated Helicase BACH1 Is Required for Timely Progression through S PhaseMolecular and Cellular Biology, 2007
- TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomesOncogene, 2007
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005